Could it be OCD or PTSD?

I do not believe the authors of “Afraid to leave home,” (Cases That Test Your Skills, CURRENT PSYCHIATRY, June 2009, p. 60-68) adequately defended their rationale for dismissing a diagnosis of obsessive-compulsive disorder (OCD) and did not consider posttraumatic stress disorder (PTSD) for Mr. B, the patient described in the article. DSM-IV clearly states that the person exhibits either obsessions or compulsions; both are not needed for a diagnosis. The patient was described as having “intense fear of bridges, upper-floor windows, express buses, subways, [and] riding in speeding vehicles,” which leads him to have intrusive, ego-dystonic thoughts that are ruminative; and he “avoids these triggers at all costs.” Clinically these sound like obsessions, which would qualify for OCD if he met other criteria, which—based on the case—he did. Furthermore, Mr. B was actively avoiding multiple situations when he felt he might harm himself. Avoidance is a common, often overlooked component of OCD that can reduce anxiety.

It would have been more helpful if Drs. Klein and Myers had described why they felt the patient did not have OCD or PTSD. It seems Mr. B would—if willing and not psychotic—have been a good candidate for exposure response prevention therapy. With such an anxious patient, this therapy could have been started as a home-based program. In addition I feel the authors did not consider the PTSD diagnosis stemming from the fear of relapse of his psychosis, which added to the clinical picture.

Megan Toufexis, DO
Child and adolescent psychiatry fellow
University of South Florida
Tampa, FL

the situations associated with it, and his hypervigilance could be better explained by residual paranoia of his main disease process, which is schizophrenia, chronic paranoid type.

Carolina A. Klein, MD
Clinical assistant instructor
SUNY Downstate Medical Center
Brooklyn, NY

References

Correction
A staff-written summary of a presentation by Marlene P. Freeman, MD, (CURRENT PSYCHIATRY, May 2009, p. 56) paraphrased her as saying “atypical antipsychotics may pose a lower risk of fetal malformations compared with lithium or anticonvulsants.” Dr. Freeman did not make this statement and states that available data are insufficient to support this comparison.

She wishes to clarify what the scientific evidence supports when treating bipolar disorder in pregnant patients:

“Because relapse rates for bipolar women who discontinue medication during pregnancy are high, it is recommended that patients consider the serious risks of untreated bipolar disorder as well as medication exposure. Valproate appears to be the mood stabilizer associated with the greatest teratogenic potential. Among the anticonvulsants, lamotrigine appears to have the most favorable reproductive safety profile, and lithium appears to have a much lower risk of teratogenicity than was thought years ago, with a very low absolute risk of malformations with first-trimester exposure. More data are needed to inform the use of atypical antipsychotics across pregnancy and breast-feeding.”